# Stryker (SYK) Financial Model Free Excel 3-statement financial model and company analysis for Stryker. - Canonical: https://finamodel.com/companies/stryker - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/SYK.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario planning tool for Stryker Corporation to assess the impact of procedural volume recovery, capital equipment demand, and recent major acquisitions on long-term free cash flow generation. ## Company Overview Stryker Corporation is a global leader in medical technologies, providing innovative products and services that help improve patient and healthcare outcomes. The company operates a decentralised model focusing on medical devices, surgical equipment, neurotechnology, and orthopaedic implants. Business segments include: * MedSurg and Neurotechnology (approximately 62% of revenue) * Orthopaedics (approximately 38% of revenue) Key geographies are heavily weighted towards the United States (approximately 75% of revenue), with International markets making up the remaining 25%. The business model is asset-light in manufacturing but heavily reliant on continuous R&D and a massive direct sales force, generating a mix of recurring revenue from consumables/implants and lumpy revenue from capital equipment like the Mako robotic system. Stryker holds a top-tier competitive position alongside peers such as J&J MedTech, Medtronic, and Zimmer Biomet. Recent major events include the 2024 segment realignment (renaming "Orthopaedics and Spine" to "Orthopaedics") and the 2025 acquisition of Inari Medical for approximately $5.0 billion to expand its vascular portfolio. ## Revenue Deep Dive ### MedSurg and Neurotechnology * **Segment name:** MedSurg and Neurotechnology * **Revenue driver formula:** (Capital Equipment Volume x Average Selling Price) + (Consumables Volume x Price per Unit) * **Historical growth rate:** 10% to 12% CAGR * **Key growth levers and headwinds:** Driven by hospital capital expenditure budgets, Mako robotic system installations, and the expansion of neurovascular procedures. Headwinds include hospital staffing shortages and macroeconomic constraints on capital budgets. * **Pricing dynamics:** Highly competitive but supported by continuous product innovation; pricing typically contributes a slightly positive impact (0.5% to 1.0%). * **Revenue recognition notes:** Capital equipment is recognised upon installation and acceptance; consumables are recognised upon shipment or usage in the hospital. * **Seasonality:** Q4 is historically the strongest quarter due to the exhaustion of hospital capital budgets and patients meeting annual health insurance deductibles. ### Orthopaedics * **Segment name:** Orthopaedics * **Revenue driver formula:** Implant Volume x Average Selling Price * **Historical growth rate:** 8% to 10% CAGR * **Key growth levers and headwinds:** Driven by elective surgery volumes (hips, knees), an aging population, and the shift of procedures to Ambulatory Surgery Centres (ASCs). Headwinds include pricing pressure from hospital procurement groups. * **Pricing dynamics:** Structurally faces slight pricing headwinds (negative 0.5% to flat) offset by strong volume growth. * **Revenue recognition notes:** Often recognised when the implant is consumed during surgery (consignment inventory model). * **Seasonality:** Q4 is the strongest quarter due to elective procedure scheduling before year-end insurance deductible resets. ## Cost Structure ### Variable Costs / COGS * **Line-by-line breakdown:** Manufacturing labour, raw materials (titanium, specialised plastics, electronics), freight, sterilisation, and tariffs. * **Gross margin range:** 64.0% to 65.5% (adjusted basis over the last 5 years). * **Key input costs and commodity exposures:** Titanium, electronic components for capital equipment, and global freight rates. * **How COGS scales with revenue:** Relatively linear, though product mix (e.g., higher margin neurotechnology vs lower margin standard beds) drives overall gross margin fluctuations. ### Operating Expenses * **R&D:** Typically 6.0% to 6.5% of revenue (approximately $1.62 billion in 2025); covers clinical trials, software development for robotics, and new implant design. * **SG&A:** Typically 33.0% to 35.0% of revenue; heavily driven by the massive direct sales force, commission structures, and marketing. * **Depreciation & Amortisation:** High amortisation expense due to serial acquisitions; typically 5% to 7% of revenue, heavily skewed towards intangible amortisation. * **Stock-Based Compensation:** Approximately 1.0% to 1.5% of revenue. * **Restructuring / one-time charges:** Frequent due to continuous M&A integration (e.g., Inari Medical integration costs). ### Margin Profile * **Gross margin:** 64.0% to 65.5% (adjusted). * **EBITDA margin:** 28.0% to 30.0% (adjusted). * **Operating margin:** 25.0% to 26.5% (adjusted, reaching 26.3% in 2025). * **Margin trend:** Expanding. The company successfully executed a plan to return to 2019 adjusted operating margin levels by 2025, driven by pricing discipline and volume leverage. ## Balance Sheet Structure * **Total assets:** Approximately $40 billion to $45 billion. * **Key asset categories:** Goodwill and intangible assets dominate the balance sheet due to a highly acquisitive growth strategy. * **Goodwill & intangibles as % of total assets:** Typically 55% to 65%. * **Working capital profile:** * **Days Sales Outstanding (DSO):** 55 to 65 days. * **Days Inventory Outstanding (DIO):** 140 to 160 days (structurally high due to the need to keep surgical implant sets in hospital consignment). * **Days Payable Outstanding (DPO):** 45 to 55 days. * **Net working capital as % of revenue:** Positive, typically 15% to 20%. * **Is working capital positive or negative?** Positive. The company consumes cash for working capital as it grows, primarily to fund inventory in the field. * **PP&E:** Manufacturing facilities, surgical instruments loaned to hospitals, and office space. Useful lives range from 3 to 15 years for equipment. * **Right-of-use assets / operating leases:** Material but manageable, typically $500 million to $700 million. ## Capital Expenditure & Investment * **Capex as % of revenue:** 2.0% to 3.0%. * **Maintenance capex vs. growth capex:** Approximately 40% maintenance, 60% growth (new manufacturing lines, surgical instrument sets). * **Major capex programmes underway or planned:** Expansion of manufacturing capacity for Mako robots and neurovascular products. * **Capitalised software / development costs:** Moderate, primarily related to internal ERP systems and digital healthcare platforms. * **M&A pattern:** Serial acquirer. Mix of frequent bolt-on acquisitions and occasional transformational deals (e.g., Wright Medical, Inari Medical). * **Typical acquisition multiple paid:** 4.0x to 6.0x forward revenue for high-growth MedTech assets. ## Debt & Capital Structure * **Total debt:** Approximately $15.9 billion (2025). * **Net debt:** Approximately $11.8 billion (assuming $4.1 billion in cash). * **Debt/EBITDA ratio:** 2.0x to 2.5x (management targets rapid deleveraging post-acquisitions). * **Credit rating:** Investment grade (typically BBB+ / Baa1). * **Key debt instruments:** Senior unsecured notes, a $3.0 billion revolving credit facility maturing in 2030, and commercial paper. * **Maturity profile:** Well-laddered with a mix of near-term commercial paper and long-term bonds extending beyond 10 years. * **Interest rate profile:** Predominantly fixed-rate bonds, with a weighted average cost of debt around 3.5% to 4.5%. * **Covenants:** Standard investment-grade covenants; no restrictive financial maintenance covenants on the bonds. * **Share repurchase programme:** Active but secondary to M&A; used primarily to offset dilution from stock-based compensation. * **Dividend policy:** Consistent dividend payer; payout ratio typically 30% to 35% of net income, growing annually. ## Cash Flow Characteristics * **Operating cash flow conversion:** Strong, typically 110% to 120% of reported net income due to high non-cash amortisation charges. * **Free cash flow margin:** 15.0% to 18.0% of revenue. * **Major non-cash items that bridge net income to OCF:** Amortisation of acquired intangibles, depreciation, stock-based compensation, and impairment charges. * **Working capital cash flow impact:** Inventory is a persistent use of cash due to the consignment model for orthopaedic implants. * **Capex intensity:** Low (2.0% to 3.0% of revenue), making the business highly cash generative. * **Cash tax rate vs. GAAP effective tax rate:** Cash taxes are generally lower than the GAAP effective tax rate (14% to 16%) due to tax deductions on intangible amortisation and stock-based compensation benefits. ## Sheet Structure 1. **Assumptions**: Contains all hardcoded inputs for revenue growth, margins, working capital days, capex, and debt terms. 2. **Revenue Build**: Projects revenue separately for MedSurg and Neurotechnology, and Orthopaedics, driven by volume and price assumptions. 3. **Income Statement**: Consolidated P&L from Revenue down to Net Income, explicitly separating Amortisation of Intangibles to allow for Adjusted EPS calculations. 4. **Balance Sheet**: Standard assets, liabilities, and equity. Must include specific lines for Goodwill, Intangible Assets, and Consignment Inventory. 5. **Cash Flow Statement**: Indirect method starting from Net Income, adding back D&A and stock-based compensation, adjusting for working capital, capex, M&A, debt issuance/repayment, and dividends. 6. **Debt Schedule**: Tracks commercial paper, revolving credit facility, and senior notes, calculating interest expense based on average balances. 7. **Working Capital Schedule**: Calculates Accounts Receivable, Inventory, and Accounts Payable based on DSO, DIO, and DPO assumptions. 8. **Depreciation & Amortisation Schedule**: Waterfalls for existing PP&E and Intangibles, plus new capex and assumed M&A additions. 9. **Valuation**: DCF model using unlevered free cash flow, WACC calculation, and terminal multiple approach. ## Key Financial Relationships 1. MedSurg and Neurotechnology Revenue = Prior Year MedSurg and Neurotechnology Revenue * (1 + MedSurg Volume Growth + MedSurg Price Growth) 2. Orthopaedics Revenue = Prior Year Orthopaedics Revenue * (1 + Orthopaedics Volume Growth + Orthopaedics Price Growth) 3. Total Net Sales = MedSurg and Neurotechnology Revenue + Orthopaedics Revenue 4. Cost of Sales = Total Net Sales * (1 - Gross Margin %) 5. R&D Expense = Total Net Sales * R&D Margin % 6. SG&A Expense = Total Net Sales * SG&A Margin % 7. Adjusted Operating Income = Total Net Sales - Cost of Sales - R&D Expense - SG&A Expense (excluding acquisition-related amortisation) 8. Accounts Receivable = (Total Net Sales / 365) * DSO 9. Inventory = (Cost of Sales / 365) * DIO 10. Accounts Payable = (Cost of Sales / 365) * DPO 11. Interest Expense = Average Total Debt * Weighted Average Interest Rate 12. Adjusted Net Earnings = Adjusted Operating Income - Interest Expense - Adjusted Taxes 13. Free Cash Flow = Operating Cash Flow - Capital Expenditures ## Cross-Sheet Dependencies * The **Assumptions** sheet dictates all drivers across the model. * The **Revenue Build** feeds the top line of the **Income Statement**. * The **Income Statement** generates Net Income, which feeds the top of the **Cash Flow Statement** and Retained Earnings on the **Balance Sheet**. * The **Working Capital Schedule** uses Revenue and COGS from the **Income Statement** to calculate balance sheet accounts, and the year-over-year change feeds the **Cash Flow Statement**. * The **Debt Schedule** uses the cash shortfall/surplus from the **Cash Flow Statement** to draw down or pay down the revolver, which then calculates Interest Expense for the **Income Statement**. This creates a circular reference that must be managed with a circuit breaker toggle. * The **Cash Flow Statement** ending cash balance feeds the **Balance Sheet** cash line. ## Sign Convention * Revenue, expenses, assets, liabilities, and equity are entered and displayed as positive numbers on their respective schedules. * On the Income Statement, expenses are subtracted from revenue to calculate profit lines. * On the Cash Flow Statement, cash inflows (e.g., net income, depreciation, increases in liabilities) are positive, while cash outflows (e.g., capex, dividends, increases in assets) are negative. * Contra-asset accounts (like accumulated depreciation) are displayed as positive numbers but subtracted from gross assets to yield net assets. ## Things Most Likely to Go Wrong * The company changed its segment reporting in 2024, renaming "Orthopaedics and Spine" to "Orthopaedics" and moving interventional spine to Neuro Cranial. Historical data prior to 2024 must be adjusted to match the new reporting structure. * Stryker reports a massive gap between GAAP and Adjusted earnings due to acquisition-related intangible amortisation and restructuring charges. The model must explicitly forecast Adjusted Operating Margin to align with management guidance. * Inventory days (DIO) are structurally much higher than standard manufacturing companies due to the surgical consignment model; assuming standard industrial DIO will drastically understate working capital needs. * Foreign currency translation can swing reported revenue by 1% to 3% YoY; the model should ideally forecast on a constant currency basis and apply an FX overlay if necessary. * M&A is a core part of the strategy. A static model with no future M&A will overstate cash build-up and understate future intangible amortisation. * The effective tax rate benefits significantly from stock-based compensation windfalls; normalising the tax rate without accounting for this will understate net income. * Capital expenditures are relatively low, but the company spends heavily on surgical instruments that are placed in hospitals; these must be properly capitalised and depreciated. * Pricing in Orthopaedics is generally negative, while MedSurg pricing is slightly positive. Applying a single corporate pricing assumption will distort segment-level gross margins. ## Validation Checks * Adjusted Gross Margin should remain in the 64.0% to 65.5% range; flag if outside this band. * Adjusted Operating Margin should be approximately 26.0% to 26.5% based on management's 2025 targets. * Capex as a % of revenue should run between 2.0% and 3.0%. * OCF/Net Income conversion should consistently be >1.1x due to heavy non-cash amortisation. * Debt/EBITDA should remain below 3.0x; if it exceeds this, the model should flag a potential credit rating downgrade risk. * Balance sheet must balance: Total Assets = Total Liabilities + Equity in every forecasted period. * Inventory days (DIO) must remain above 140 days to reflect the consignment business model. * Dividend payout ratio should remain within 30% to 35% of adjusted net earnings. ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | MedSurg & Neurotechnology Volume Growth | 9.5 | % | Based on 2025 actual organic volume growth | | MedSurg & Neurotechnology Price Growth | 0.8 | % | Based on 2025 actual pricing impact | | Orthopaedics Volume Growth | 9.0 | % | Based on 2025 actual organic volume growth | | Orthopaedics Price Growth | -0.1 | % | Based on historical slight pricing headwinds in implants | | Adjusted Gross Margin | 65.3 | % | Based on full-year 2025 adjusted gross margin | | R&D as % of Sales | 6.5 | % | Consistent historical average to support innovation | | SG&A as % of Sales | 33.0 | % | Required to support massive direct sales force | | DSO (Days Sales Outstanding) | 60 | Days | Historical average for hospital receivables | | DIO (Days Inventory Outstanding) | 150 | Days | Reflects heavy consignment inventory requirements | | DPO (Days Payable Outstanding) | 50 | Days | Historical average | | Capex as % of Sales | 2.5 | % | Historical average for maintenance and growth | | Effective Tax Rate (Adjusted) | 15.0 | % | Management guidance for adjusted effective tax rate | | Weighted Average Interest Rate | 4.0 | % | Based on current debt stack and recent bond issuances | | Dividend Payout Ratio | 32.0 | % | Aligns with historical capital return policy | | WACC | 7.5 | % | Standard discount rate for large-cap MedTech | | Terminal Growth Rate | 2.5 | % | Long-term GDP plus healthcare premium growth | ## Data Sources & Benchmarks * **Filings:** SEC EDGAR (Form 10-K, 10-Q, 8-K), Stryker Investor Relations website. * **Key Peers:** Medtronic (MDT), Johnson & Johnson MedTech (JNJ), Zimmer Biomet (ZBH), Boston Scientific (BSX). * **Industry Data:** IQVIA for procedural volume data, American Academy of Orthopaedic Surgeons (AAOS) for joint replacement trends. * **Consensus Estimates:** FactSet or Bloomberg for forward-looking analyst estimates to validate model outputs. ## Sources * Stryker Corporation Q4 2025 Earnings Release (January 29, 2026) * Stryker Corporation 2025 Form 10-K * Stryker Corporation 2024 Comprehensive Report * Quiver Quantitative Insider Trading and Government Contracts Data (February 2026) * Investing.com Q4 2025 Earnings Call Transcript Summary --- ## Frequently asked questions ### What does Stryker Corporation do? Stryker Corporation is a global leader in medical technologies, providing innovative products and services that improve patient and healthcare outcomes. The company operates through segments like MedSurg and Neurotechnology, and Orthopaedics, focusing on medical devices, surgical equipment, and implants. ### How does Stryker generate revenue? Stryker generates revenue from a mix of recurring sales from consumables and implants, alongside lumpy revenue from capital equipment such as the Mako robotic system. Its business model relies on continuous research and development and a large direct sales force, primarily in the United States. ### What is the assumed capital expenditure percentage of revenue for Stryker in financial models? In financial models for Stryker, the assumed capital expenditure (Capex) is approximately 3.36% of revenue. This assumption helps project the company's investment needs for maintaining and expanding its operational assets, including manufacturing capacity and surgical instrument sets. ### What is the purpose of the Stryker financial model? The Stryker financial model serves as a comprehensive tool for equity valuation and scenario planning. It helps assess how factors like procedural volume recovery, capital equipment demand, and recent major acquisitions impact the company's long-term free cash flow generation. ### Can I download an Excel financial model for Stryker? Yes, a downloadable Excel financial model is available for Stryker Corporation. This model provides a detailed forecast horizon from fiscal year 2026 through fiscal year 2030, offering projections for various financial metrics. ### How does Stryker's working capital profile impact its cash flow? Stryker has a positive working capital profile, meaning the company consumes cash as it grows, primarily to fund inventory in the field. This is partly driven by structurally high Days Inventory Outstanding (DIO) of 140 to 160 days, necessary for keeping surgical implant sets in hospital consignment. [Interactive forecast calculator](https://finamodel.com/companies/stryker/forecast)